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http://dx.doi.org/10.1016/j.ccell.2014.09.015SUMMARYAutophagy promotes tumor growth by generating nutrients from the degradation of intracellular structures.
Here we establish, using shRNAs, a dominant-negative mutant, and a pharmacologic inhibitor, mefenamic
acid (MFA), that the Transient Receptor Potential Melastatin 3 (TRPM3) channel promotes the growth of clear
cell renal cell carcinoma (ccRCC) and stimulates MAP1LC3A (LC3A) and MAP1LC3B (LC3B) autophagy.
Increased expression of TRPM3 in RCC leads to Ca2+ influx, activation of CAMKK2, AMPK, and ULK1, and
phagophore formation. In addition, TRPM3 Ca2+ and Zn2+ fluxes inhibit miR-214, which directly targets
LC3A and LC3B. The von Hippel-Lindau tumor suppressor (VHL) represses TRPM3 directly through miR-
204 and indirectly through another miR-204 target, Caveolin 1 (CAV1).INTRODUCTION
Clear cell renal cell carcinoma (ccRCC) is a malignant kidney
cancer distinguished by early loss of the von Hippel-Lindau
tumor suppressor protein (VHL), leading to accumulation of
the hypoxia-inducible transcription factor (HIF). Induction of
HIF-responsive genes provides access to extracellular nutrients
andoxygen through an increasedblood supply anda shift toward
glycolytic metabolic pathways, both promoting tumor growth.
Antiangiogenic therapies are currently the approach of choice
in treating metastatic ccRCC (Coppin et al., 2011). One of the
most important factorsdiminishing the successof antiangiogenicSignificance
Metastatic ccRCC is a largely incurable disease, and the existin
tors, and the mTOR pathway are only partially effective. Here w
ccRCC oncogenesis that can be subject to experimental thera
204 tumor suppressors, involves oncogenic activity of the TRP
through Ca2+ and Zn2+ influx.We showed that a small molecule
manipulations of TRPM3. This is an important proof of concept
treatment of ccRCC.
738 Cancer Cell 26, 738–753, November 10, 2014 ª2014 Elsevier Inctherapies is that cancer cells adapt to exogenous nutrient depri-
vation by activating mechanisms of autophagy (Hu et al., 2012).
Autophagy is a homeostatic, tightly regulated process that
provides organelle quality control and generates intracellular nu-
trients from lysosomal processing of cellular structures. It is
generally believed that autophagy is tumor-suppressing in the
early stages of cancer, protecting cells from oxidative stress
and resulting in genomic instability (White and DiPaola, 2009).
However, during tumor growth, many cancers become addicted
to autophagy as a source of nutrients. Moreover, autophagy is
activated by different cancer therapies, causing resistance to
treatment and promoting the use of autophagic inhibitors suchg treatments targeting angiogenesis, tyrosine kinase recep-
e discovered a network in the regulation of autophagy and
peutics. This pathway, downstream from the VHL and miR-
M3 channel and its role in controlling autophagic programs
inhibitor of TRPM3,MFA, recapitulates the effects of genetic
showing that TRPM3 represents an actionable target for the
.
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including those for ccRCC (Lotze et al., 2013).
Our laboratory demonstrated previously that the growth of
ccRCC depends on active autophagy and correlates with the
expression of an autophagy regulator, LC3B (Mikhaylova et al.,
2012). We showed that VHL regulates oncogenic autophagic
pathways by inducing miR-204, which represses the expression
of LC3B. Loss of VHL and the resulting loss of miR-204 con-
tribute to the active LC3B-mediated autophagic pathway. In
parallel, VHL, through repression of HIF, stimulates the expres-
sion and activity of LC3C, an LC3B paralog, inducing tumor-sup-
pressing autophagy.
MiR-204 is expressed from intron 6 of the gene encoding a
transient receptor potential nonselective cation channel, sub-
family M, member 3 (TRPM3), which conducts Ca2+ and Zn2+
ions (Harteneck, 2005; Oberwinkler and Phillipp, 2007; Wagner
et al., 2010). Both TRPM3 and miR-204 show enriched expres-
sion in the human kidney (Grimm et al., 2003). It is activated by
a decrease in osmolality (Grimmet al., 2003), endogenous sphin-
gosine and dihydrosphingosine (Grimm et al., 2005), and extra-
cellular exposure to the hormone pregnenolone sulfate (PS)
(Wagner et al., 2008; Naylor et al., 2008). TRPM3 is specifically
inhibited by mefenamic acid (MFA) (Klose et al., 2011). VHL-
mediated induction of miR-204 expression correlates with
VHL-induced expression of two short TRPM3 transcripts but
not TRPM3 transcripts encoding the full-size functional channel
protein (Mikhaylova et al., 2012).
Because of the genomic localization of miR-204 within the
TRPM3 gene and because several members of the TRPM family
are implicated in various malignancies, we investigated the
expression, activity, andmechanismof TRPM3activity in ccRCC.
RESULTS
TRPM3 Promotes Tumor Growth in ccRCC
Analysis of the ratio of TRPM3 protein in ccRCC samples to
matched kidney samples, using semiquantitative western blot-
ting of total protein lysates, revealed that the levels of TRPM3
were increased in 64% (42 of 66) tumors with VHL-inactive
(mutated, deleted, or hypermethylated) but only in 33% (8 of
24) tumorswithwild-typeVHL (Figures 1A and1B). Immunostain-
ing with an anti-TRPM3 antibody showed intense membranous
and some diffuse cytoplasmic staining in ccRCC, whereas
normal kidney showed staining in the basolateral membrane
(Figure 1C).
We then generated stable knockdowns of the TRPM3 channel
(TRPM3KD) using lentiviral small hairpin RNAs (shRNAs) in
786-O or A498 VHL() cells (Figure S1A available online).
TRPM3KD decreased PS-induced (Figure S1B) and constitutive
(Figure S1C) intracellular calcium concentration ([Ca2+]i), indi-
cating the functional effectiveness of the knockdown.
TRPM3KD inhibited the formation and growth of tumors from
these cells in orthotopic xenografts (Figures 1D and 1E). The
expression of dominant-negative TRPM3 (TRPM3DN) mutated
in the pore-forming domain (PYW > AAA), which inhibits the ac-
tivity of the endogenous channel by interfering with the forma-
tion of homotetramers necessary for channel activity (Hoffmann
et al., 2010; Figure S1D), diminished the growth of orthotopic
xenograft tumors (Figures 1D and 1E). Growth inhibition was re-Canflected by a decrease in staining for the proliferation marker
Ki67 (Figure 1F).
The role of TRPM3 in tumor growth was further established by
reconstitution of TRPM3KD (shRNA I) cells with shRNA-resistant
TRPM3 (TRPM3R) (Figure S1E). TRPM3R-expressing cells for-
med tumors that were comparable in size and incidence with tu-
mor formed by cells expressing endogenous TRPM3 (Figures
1G–1K). Note that TRPM3KD cells formed only three small tu-
mors (19%) compared with control cells (100%) and TRPM3R
cells (88%) (Figure 1H), and they were filled with acellular protei-
nous material (Figure 1J) with very few Ki67-stained nuclei (Fig-
ure 1K). Because these tumors were too small to measure with
calipers, they are not shown in Figure 1G. TRPM3 rescue was
accompanied by recovery of Ki67 staining (Figure 1K). The tu-
mor-suppressive effect of TRPM3KD was not accompanied by
an increase in apoptosis, shown by PARP cleavage and cleaved
caspase 3 staining (Figures S1F and S1G). These data demon-
strate that increased TRPM3 expression is a frequent event sup-
porting the growth of ccRCC.
TRPM3 Expression Is Regulated by miR-204
Consistent with the increased expression of TRPM3 in tumors
with inactive VHL (Figure 1A), human RCC cell lines with inactive
VHL (786-O and A498) showed higher levels of TRPM3 expres-
sion compared with RCC cell lines with wild-type endogenous
VHL (Caki-1) (Figure 2A). Reconstitution of VHL in 786-O and
A498 cells (VHL(+)) decreased the expression of TRPM3 in these
cell lines (Figure 2B). This regulation was not mediated at the
level of mRNA (Figure S2A) or proteasomal or lysosomal degra-
dation (data not shown).
While investigating the molecular mechanism of VHL-regulated
TRPM3 expression, we observed that the 30 UTR of the TRPM3
transcript has a putative miR-204-binding site (TargetScan, Fig-
ure S2B), suggesting that miR-204 may inhibit the translation of
its host gene product. Consistent with this hypothesis, transduc-
tion of an anti-miR-204 ZIP lentivirus into three different VHL(+)
RCC cell lines with high levels of endogenous miR-204 (Mikhay-
lovaetal., 2012) inducedTRPM3proteinaccumulation (Figure2C).
Further expression of pre-miR-204 was without effect in these
cells (Figure S2C). However, transduction of a pre-miR-204 lenti-
virus reduced the expression of TRPM3 protein in VHL() RCC
cell lines that express very low levels of endogenousmiR-204 (Fig-
ure 2D). Transduction of the anti-miR-204 ZIP lentivirus was
without further effect (Figure S2D). Cotransfection of the lucif-
erase-TRPM3 30 UTR reporter construct with pre-miR-204 signif-
icantly repressed the activity of the reporter construct containing
a wild-type but not a mutated miR-204 binding site (Figure 2E).
The significant inverse correlation between steady-state levels of
TRPM3proteinandmiR-204 inextracts fromnormalkidney further
supports thesefindings (Figures2Fand2G).These results indicate
that TRPM3 is a direct target of its own intronic miR-204.
Expression of TRPM3 Requires Another Direct Target
of miR-204, Caveolin 1
Caveolin 1 (CAV1) is a protein highly expressed in ccRCC. Its
expression levels correlate with disease stage (Horiguchi et al.,
2004; Tamaskar et al., 2007; Campbell et al., 2008; Steffens
et al., 2011).We found higher levels of CAV1 in ccRCC compared
with normal kidney in matched pairs by semiquantitativecer Cell 26, 738–753, November 10, 2014 ª2014 Elsevier Inc. 739
Figure 1. The TRPM3 Channel Is Overexpressed in ccRCC and Regulates the Growth of Xenograft Tumors
(A) Box-and-whisker plot showing the quantification of the tumor/kidney ratio of TRPM3 protein levels in tumors with wild-type (WT) or inactive VHL. The boxes
represent lower and upper quartiles separated by themedian (thick horizontal line), and the whiskers extend to theminimum andmaximum values.Means ± SD of
each distribution are indicated by closed dots and crosses on the whiskers, respectively.
(B) Representative western blot showing the expression of TRPM3 protein in lysates of ccRCCs (T) with deleted VHL compared with adjacent kidneys (K).
Different bands detected by the antibody may correspond to different splice variants of TRPM3 (Ensembl) or posttranslational modifications.
(C) Representative images of TRPM3 immunocytochemistry in sections of two different ccRCCs and normal kidney.
(legend continued on next page)
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Figure 2. VHL Inhibits TRPM3 Expression through Direct Targeting by miR-204
(A) Western blot showing levels of TRPM3 protein in VHL() cells and in the Caki-1 cell line with endogenous VHL.
(B) Western blot showing TRPM3 protein levels in 786-O and A498 cells with reconstituted VHL (VHL(+)) compared with isogenic VHL() cells.
(C) Western blot showing the effects of anti-miR-204 on the expression of TRPM3 protein in the indicated VHL(+) RCC cells.
(D) Western blot showing the effects of pre-miR-204 on the expression of TRPM3 protein in the indicated VHL() RCC cells.
(E) Effects of miR-204 on the activity of the luciferase (Luc) reporter construct containing theWT or mutated miR-204 binding site (mut) 30 UTR of TRPM3 in 786-O
VHL() cells. The ratio of luciferase activity in cells transduced with wild-type miR-204 to the activity in cells transduced with a nontargeting lentivirus control is
shown. Error bars indicate SEM.
(F) Representative western blot showing the expression of TRPM3 protein (top) in nine kidneys with low and high levels of miR-204 (bottom).
(G) Regression analysis showing the negative correlation between the normalized TRPM3 protein level and the normalized miR-204 level in human kidneys. Each
dot represents a sample, and the solid line represents the linear regression fit, with the Pearson correlation coefficient (r) as well as the slope and intercept of the
fitted line shown in the upper left corner of the box.
See also Figure S2.
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TRPM3 Channel in Clear Cell Renal Cell Carcinomaimmunoblotting of CAV1 protein (Figure S3A). This resulted from
higher levels of CAV1 in more advanced tumors, grades G3-G4,
but not G1-G2 (Figure S3B). The levels of CAV1were significantly
higher in ccRCC with inactive VHL compared with tumors with
wild-type VHL (Figure S3C). We found higher levels of CAV1 in
RCC cell lines with inactive VHL compared to Caki-1 cells with(D) Bar graph showing the incidence andweight of tumors formed in orthotopic xen
and III), and TRPM3DN. The tumor weight includes the kidney in which the tu
endogenous TRPM3 were stably transfected with scrambled pLKO.1 vector.
(E) Hematoxylin and eosin (H&E) staining of representative sections of xenograf
tumors from kidneys in the case of tumors formed by cells with TRPM3KD(shRN
(F) Representative sections from tumors formed by 786-O VHL() cells shown
compared with the total number of nuclei.
(G) Box-and-whisker plot showing the subcutaneous growth of tumors formed b
represent points that are outside of the 1.5 interquartile range from the box. Day
(H) Examples and incidence of tumors formed by 786-O VHL() cell lines with th
(I) Weight of the collected tumors formed by 786-O VHL() cell lines with the ind
(J) Representative H&E staining of sections from tumors shown in (H).
(K) Representative sections from subcutaneous tumors in (H) stained for Ki67 and
of nuclei.
Unless indicated otherwise indicated, all scale bars are 50 mm, and error bars in
Canendogenous wild-type VHL (Figure 3A) and saw a significant
reduction in CAV1 protein expression in VHL() cells upon
reconstitution of VHL (Figure 3B). Although this decrease was
accompanied by a decrease in the levels of mRNA (Figure 3B),
in agreement with a previous report of CAV1 regulation by HIF
(Wang et al., 2012), the decrease was not sufficient to accountografts by VHL() cells with endogenous (endog.) TRPM3, TRPM3KD (shRNA I
mor was growing. NK, average weight of normal kidney. Control cells with
t tumors formed by 786-O VHL() cells shown in (D). The clear separation of
A III) or TRPM3DN is indicated by a black dashed line.
in (D) stained for Ki67 and bar graph quantification of Ki67-positive nuclei
y 786-O VHL() cells with endogenous TRPM3 or TRPM3R cells. Open circles
1 corresponds to the time point 2.5 weeks after injections.
e indicated status of TRPM3. Scale bar, 1 cm.
icated status of TRPM3.
bar graph quantification of Ki67-positive nuclei compared with the total number
dicate SEM. See also Figure S1.
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Figure 3. CAV1 Is a miR-204 Target and Regulates Expression of TRPM3
(A) Western blot showing levels of CAV1 protein in the indicated cell lines.
(B) Expression of CAV1 protein and mRNA using western blot (left) and qRT-PCR (right) in 786-O and A498 VHL(+) cells compared with the isogenic VHL() cells.
Error bars indicate SD. IB, immunoblot.
(C) Western blot showing the effects of pre-miR-204 on the expression of CAV1 protein in VHL() cells.
(D) Western blot showing the effects of anti-miR-204 on the expression of CAV1 protein in VHL(+) cells.
(E) Effects of miR-204 on the activity of a luciferase reporter containing the WT or mutated miR-204 binding site chimeric 30 UTR of CAV1 in 786-O VHL() cells.
Error bars indicate SEM.
(F) Effects of CAV1KD on the expression levels of TRPM3 protein in 786-O VHL() cells.
(G) Effects of stable overexpression of FLAG-tagged CAV1 on TRPM3 protein levels in two different pools (P1 and P2) of 786-O VHL(+) cells. Endog., endogenous.
(H) Regression analysis demonstrating the positive correlation between normalized TRPM3 and normalized CAV1 protein levels in human ccRCCs. The analysis
was performed as in (G).
(I) Representative western blot showing protein levels of TRPM3 and CAV1 in 14 human ccRCCs.
See also Figure S3.
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conserved miR-204 site (Figure S3D). We found that exogenous
pre-miR-204 substantially repressed levels of CAV1 protein (Fig-
ure 3C) with minimal effects on CAV1 mRNA (Figure S3E) in
VHL() cells. Consistent with the fact that these cells express
little endogenous miR-204, anti-miR-204 did not affect the
expression of CAV1 protein (Figure S3F). In contrast, expression
of CAV1 protein, but not mRNA, was induced by the expression742 Cancer Cell 26, 738–753, November 10, 2014 ª2014 Elsevier Incof anti-miR-204 (Figure 3D; Figure S3E) and was not affected by
pre-miR-204 (Figure S3G) in VHL(+) cells that express endoge-
nous miR-204. Wild-type but not a mutated 30 UTR of CAV1
conferred miR-204 regulation to a luciferase reporter (Figure 3E).
This indicates that the loss of VHL contributes to high levels of
CAV1 in ccRCC through the loss of miR-204.
Knockdown of CAV1 (CAV1KD) reduced the expression of
TRPM3 in VHL() cells to levels similar to those in VHL(+) cells.
Cancer Cell
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UTR in VHL(+) cells induced expression of TRPM3 (Figure 3G).
These effects were only partially mediated by changes in
TRPM3 mRNA (Figure S3H). We also found a significant correla-
tion between levels of CAV1 and TRPM3 in human ccRCC (Fig-
ures 3H and 3I). Consistent with the effects of TRPM3 on tumor
formation, CAV1KD diminished tumor formation by RCC VHL()
cells (Figure S3I), whereas overexpression of CAV1 in VHL(+)
cells increased the incidence of tumors formed by these cells
to the level formed by VHL() cells, although these tumors
were small (Figure S3J). Importantly, we found colocalization of
CAV1 and TRPM3 intracellularly and in the plasma membrane,
indicating that CAV1 plays a role in the trafficking or localization
of TRPM3 to the membrane (Figure S3K), as described similarly
for another TRP channel (Lockwich et al., 2000). These data
establish CAV1 as an upstream regulator of TRPM3 expression.
TRPM3 Regulates Autophagy
Our previous identification of miR-204 as a critical regulator of
autophagy prompted the hypothesis that TRPM3 may
contribute to autophagy regulation as well. We investigated au-
tophagic activity in VHL() control and TRPM3KD cells after
48 hr of growth under low-serum (0.1%) conditions. The number
of autophagic vesicles counted from transmission electron mi-
croscopy (TEM) sections (Figure S4A) was decreased signifi-
cantly in TRPM3KD cells (Figure 4A). Moreover, 786-O and
A498 TRPM3KD cells showed a decreased accumulation of lipi-
dated LC3A and LC3B (LC3A-II and LC3B-II) in the presence of
chloroquine (CQ) (Figure 4B; Figure S4B). A similar effect was
achieved by expression of a TRPM3DN mutant (Figure 4C; Fig-
ure S4C). The TRPM3KD effects were reversed by expression of
exogenous TRPM3R (Figure 4D). A decrease in LC3A/B-II was
also produced by knockdown of CAV1 (Figure S4D). Although
autophagic activity was also lower in TRPM3KD cells compared
with VHL() control cells under culture conditions of 10%
serum, the accumulation of LC3A/B-II in response to thapsigar-
gin under normal serum conditions was similar for the two cell
lines (Figure S4E). Because thapsigargin increases [Ca2+]i, it
can rescue diminished extracellular Ca2+ flux through TRPM3.
This evidence points to the role of TRPM3-dependent cytosolic
[Ca2+] in the regulation of autophagy. At the same time, the dif-
ferences in autophagy between control and TRPM3KD cells do
not involve mTOR because we did not detect increased mTOR
activity (Figure S4F), and inhibition of mTOR induced autophagy
in both cell types to the same degree (Figure S4E). Autophagy
dependence on TRPM3 was specific for VHL() cells.
TRPM3KD in 786-O and A498 VHL(+) cells that express little
TRPM3 did not inhibit autophagy (Figure 4E). However, expres-
sion of TRPM3WT, but not TRPM3DN, in human embryonic kid-
ney 293 (HEK293) cells induced the accumulation of LC3A/B-II
(Figure S4G), suggesting that the increased expression of
TRPM3 may force a connection with the autophagic pathway.
Consistent with immunoblotting experiments, immunostaining
for LC3B puncta in sections from orthotopic xenografts was
substantially stronger in tumors formed by VHL() cells com-
pared with tumors formed by TRPM3KD cells or cells express-
ing TRPM3DN (Figure 4F). Reconstitution of TRPM3R in cells
with TRPM3KD rescued the accumulation of LC3B puncta in
tumor cells (Figure 4G). Importantly, reconstitution of LC3BCan(Figure S4H) restored the incidence of tumor formation by
TRPM3KD cells that failed to grow tumors in xenografts models.
However, these tumors were smaller than the tumors formed by
control cells (Figure 4H).
The simultaneous regulation of LC3A and LC3B suggests that
both paralogs partner in the formation of similar autophago-
somes. We observed that endogenous LC3B coimmunoprecipi-
tated endogenous LC3A (Figure S4I) and that they exhibited
overlapping localization in 786-O and A498 VHL() cells (Fig-
ure S4J). Together these data indicate that TRPM3 is necessary
for oncogenic autophagy under starvation conditions in VHL()
RCC cells.
TRPM3 Regulates Autophagy through the Upstream
CAMKK2-ULK1 Cascade
The activity of upstream and downstream regulatory steps in the
autophagic pathway is determined from the overall number of
puncta immunolabelled for ATG16L and ATG5–ATG12, which
correspond to the phagophore formation sites (Mikhaylova
et al., 2012). We saw a significant decrease in the number of
ATG16L (Figure 5A; Figure S5A) and ATG5–ATG12 (Figure 5B;
Figure S5B) puncta in TRPM3KD cells compared with VHL()
control cells, but we did not measure changes in the steady-
state levels of ATG16L or ATG5–ATG12 conjugate by western
blot analysis (Figure 5C). This indicates that TRPM3 regulates
autophagy upstream of phagophore formation.
The role of TRPM3 in Ca2+ influx regulation is well recognized
(Grimm et al., 2003, 2005; Wagner et al., 2008; Naylor et al.,
2008, 2010), and its activity is linked to calmodulin-regulated
signaling pathways (Holakovska et al., 2012). [Ca2+]i regulates
autophagy through the calmodulin-dependent activation of
CAMKK2 and phosphorylation of AMPK (Høyer-Hansen et al.,
2007; Ghislat et al., 2012), which, in turn, phosphorylates ULKs
(Egan et al., 2011). We anticipated that the TRPM3KD-caused
decrease in [Ca2+]i (Figures S1B and S1C) would inhibit CAMKK2
and AMPK activity and, as a result, decrease ULK1 phosphory-
lation and autophagic activity.
We did measure a decrease in the phosphorylation of Thr172
of AMPKa and a decrease in ULK1 phosphorylation on Ser317 in
TRPM3KD cells compared with control cells, indicating de-
creased activity of both kinases (Figure 5D). Phosphorylation of
AMPKa Thr172 and ULK1 Ser317 were also diminished in
VHL() cells by expression of the TRPM3DNmutant (Figure S5C)
and by CAV1KD (Figure S5D). Phosphorylation of AMPKa
Thr172 and ULK1 Ser317 was recovered in TRPM3KD cells by
reconstitution of TRPM3R (Figure 5E). TRPM3KD in VHL(+) cells
did not repress either phosphorylation, consistent with the low
level of TRPM3 and a lack of connection between TRPM3 and
autophagy in these cells (Figure 5F). The effects of TRPM3 on
AMPK/ULK1 phosphorylation could be forced in HEK293 cells
transiently transfected with exogenous wild-type TRPM3 but
not TRPM3DN (Figure S5E), consistent with the effects of exog-
enous TRPM3 on LC3A/B autophagy (Figure S4G).
Next we determined the role of CAMKK2 and AMPK in the
pathway. The expression of constitutively active CAMKK2
(Green et al., 2011) in TRPM3KD cells restored autophagy,
including ULK1 and AMPK phosphorylation, to levels com-
parable with control VHL() cells (Figure 5G). Knockdown of
CAMKK2 inhibited autophagy and AMPK and ULK1cer Cell 26, 738–753, November 10, 2014 ª2014 Elsevier Inc. 743
Figure 4. The TRPM3 Channel Regulates Autophagy
(A) Bar graph quantification of the number of autophagic vesicles (top) and the cytoplasmic area (bottom) in TEM sections of 20 786-O VHL() control (stably
transfected with scrambled pLKO.1 vector [Scr]) or TRPM3KD cells. In this and all subsequent figures, if not indicated otherwise, ‘‘TRPM3KD’’ refers to
knockdowns using shRNA I.
(legend continued on next page)
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TRPM3 Channel in Clear Cell Renal Cell Carcinomaphosphorylation in VHL() cells, indicating that autophagic flux
requires CAMKK2 activity (Figure 5H). A similar effect was
achieved by treatment of VHL() cells with the CAMKK2 inhibitor
STO-609 (Figure S5F). Loss of autophagy and decreased phos-
phorylation of ULK1 and AMPK in TRPM3KD cells were rescued
by expression of constitutively active AMPK (Figure 5I), whereas
AMPKa1/AMPKa2 knockdown inhibited autophagy and ULK
phosphorylation in VHL() cells (Figure 5J). These data indicate
that high-level expression of TRPM3 in VHL() cells contributes
to oncogenic autophagy through a CAMKK2-AMPK-ULK1 regu-
latory pathway.
TRPM3 Regulates Autophagy through miR-214
A close analysis of the LC3A/LC3B-I and LC3A/LC3B-II forms by
western blot analysis showed a decrease in both forms in
TRPM3KD cells in the presence of CQ rather than a shift of the
LC3A/LC3B-II to the LC3A/LC3B-I form, as would be expected
based only on the decreased upstream input to LC3 lipidation
(Figure 4B; Figure S4B). This suggests an additional inhibition
of LC3A/B at the protein accumulation level, even if this is not re-
flected in an increased number of puncta representing early
phagophores (Figures 5A and 5B). We determined that the ef-
fects of TRPM3 activity on the accumulation of LC3A/B were
not mediated through mRNAs levels (Figure S6A) or proteasome
degradation (Figure S6B). We hypothesized that TRPM3 regu-
lates the expression of LC3A/B at translation, possibly by micro-
RNAs targeting both proteins. Subsequent analysis of the 30
UTRs of LC3A and LC3B revealed the presence of putative sites
for miR-214 (TargetScanHuman 6.2; Figure S6C), which is of
particular interest because its expression is decreased in ccRCC
compared with normal kidney (Chow et al., 2010; Osanto et al.,
2012), supporting a role of miR-214 in tumor suppression. We
found that the expression of miR-214 was induced in TRPM3KD
cells and that this effect was reversed by the expression of
TRPM3R (Figure 6A). Reconstitution of VHL in VHL() cells,
which leads to lower levels of TRPM3 (Figure 2), also induced
the expression of miR-214 (Figure 6B). The level of miR-214
was higher in the Caki-1 cell line with wild-type VHL compared
with cell lines lacking VHL (Figure 6C). The expression of exoge-
nous TRPM3WT in 786-O VHL(+) or HEK293 cells resulted in a
2-fold repression of miR-214, whereas TRPM3DN did not have
this effect (Figure 6D). Consistent with low TRPM3 activity in
VHL(+) cells, TRPM3KD in these cells had no effect on miR-
214 levels (Figure 6E). Treatment of VHL() cells with pre-miR-
214 repressed the expression of LC3A/B, whereas treatment
with anti-miR-214 had no effect (Figure 6F). In contrast, treat-
ment of TRPM3KD cells (Figure 6G) or VHL(+) cells (Figure 6H)(B) Western blot and bar graph quantification showing effects of TRPM3KD on the
of LC3-II accumulation in control cells, which is accepted as 1.
(C) Western blots showing the effects of TRPM3DN on the accumulation of LC3
(D) Western blot showing the rescue of LC3A/LC3B-II accumulation upon recons
(E) Western blot showing the effects of TRPM3KD on the accumulation of LC3A/
(F) Immunostaining for LC3B puncta in sections from respective orthotopic xen
20 mm.
(G) Immunostaining for LC3B puncta in sections from subcutaneous xenografts
(H) Incidence and weight of tumors formed in orthotopic xenografts by 786-0 VH
cells did not form tumors, similar as shown in Figure 1D.
In all panels, error bars indicate SEM. See also Figure S4.
Canwith anti-miR-214 resulted in an increase in both protein levels.
The wild-type 30 UTRs of LC3A and LC3B conferred regulation
by miR-214 to the respective luciferase reporters. This activity
was abolished with a mutated miR-214 binding site (Figure 6I).
This establishes that LC3A and LC3B are direct targets of endog-
enous miR-214.
Next we investigated the signaling pathway regulating the ex-
pression of miR-214 by TRPM3. Consistent with the effects of
TRPM3 on ULK1 phosphorylation, the expression of miR-214
was inhibited significantly in TRPM3KD cells by constitutively
active CAMKK2 or AMPKa2 (Figure 6J), whereas its expression
was induced in VHL() cells by knockdown of CAMKK2 or
AMPKa1/AMPKa2 (Figure 6K). The CAMKK2 inhibitor STO-609
also induced the expression of miR-214 (Figure S6D). In
contrast, expression of miR-214 was not affected by ULK1 or
PIK3C3 KD (Figure 6K; Figure S6E) or inhibition of CaMKII, pro-
tein kinase C, or calcineurin with specific inhibitors (Figure S6D).
A decrease in miR-214 activity using an anti-miR only partially
rescued the effects of CAMKK2 inhibition (Figure 6L), supporting
evidence that the TRPM3-CAMKK2 pathway regulates auto-
phagy at two levels: upstream at phagophore formation and
downstream through miR-214 at LC3s protein translation.
Because the TRPM3 channel also conducts Zn2+, we tested
the role of Zn2+ in autophagy regulation. First we found that
N,N,N0,N0-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN),
a specific chelator of intracellular Zn2+, inducedmiR-214 expres-
sion in VHL() but not VHL(+) cells (Figure S6F). TPEN treatment
partially recapitulated the inhibition of LC3A/LC3B by TRPM3KD
in VHL() cells (Figure S6G). TPEN did not affect ULK1 and
AMPK phosphorylation (Figure S6H), an indication that Zn2+
does not act upstream of phagophore formation. The effects
of TPEN on LC3A/LC3B accumulation in VHL() cells were
completely reversed by the expression of anti-miR-214 (Fig-
ure S6I), indicating that miR-214 levels account for the ef-
fects of Zn2+ on autophagy. These data demonstrate two parallel
mechanisms regulating miR-214 by TRPM3, one through the
activity of the CAMKK2-AMPK pathway and the other through
Zn2+ in a manner independent from the CAMKK2-AMPK
pathway.
MFA Mimics the Effects of TRPM3KD on LC3A
and LC3B Autophagy
MFA is a nonsteroidal, anti-inflammatory, Food and Drug Admin-
istration-approved drug for the treatment of pain and a specific
inhibitor of TRPM3 (Klose et al., 2011). MFA treatment mimicked
the effects of TRPM3KD on tumor formation. We treated nude
mice bearing subcutaneous xenograft tumors of 786-O oraccumulation of LC3A/LC3B-II in VHL() cells. The dashed line shows the level
A/B-II in 786-O VHL() cells. P1 and P2 are two separate pools of cells.
titution of TRPM3R in 786-0 VHL() TRPM3KD cells.
LC3B-II in VHL(+) cells.
ografts of 786-O VHL() cells with the indicated status of TRPM3. Scale bar,
of 786-O VHL() cells with the indicated status of TRPM3. Scale bar, 20 mm.
L() TRPM3KD cells with re-expressed FLAG-LC3B. Note that TRPM3KD(shI)
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Figure 5. TRPM3 Regulates Autophagy through the CAMKK2/AMPK/ULK1 Pathway
(A) Bar graph quantification of ATG-16L puncta detected by immunofluorescence staining in 786-O VHL() control and TRPM3KD cells. Error bars indicate SEM.
(B) Bar graph quantification of ATG5-ATG12 puncta detected by immunofluorescence staining in 786-O VHL() control and TRPM3KD cells. Error bars indicate
SEM.
(legend continued on next page)
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of MFA (100 mg/kg, Somchit et al., 2004) or indomethacin (IDM,
3 mg/kg, Connolly et al., 2002), a control nonsteroidal anti-in-
flammatory drug, for 9 days. The doses of both drugs were cho-
sen based on the highest doses described in the literature as
used in mice. MFA treatment resulted in a significant reduction
of tumor growth and, in some cases, tumor regression (Fig-
ure 7A). In contrast, IDM treatment did not affect tumor growth
compared with the controls (Figure 7A). Tumor growth was re-
flected by the proliferation marker Ki67. Significantly fewer
stained nuclei were seen in sections of tumors treated with
MFA compared with tumors from control or IDM-treated mice
(Figure 7B). Treatment of 786-O and A498 VHL() cells for
48 hr with concentrations of MFA known to inhibit channel activ-
ity as measured by calcium imaging (Klose et al., 2011) resulted
in the reduction of TRPM3 at the protein and mRNA levels (Fig-
ure 7C). Consistent with the TRPM3KD experiments, MFA treat-
ment reduced the accumulation of LC3A/LC3B-II and ULK1 and
AMPK phosphorylations (Figure 7D; Figure S7A). MFA treatment
diminished the number of LC3B puncta in sections from xeno-
graft tumors (Figure S7B). MFA also induced an increase in
miR-214 levels in VHL() cells (Figure 7E). In contrast, MFA
was ineffective in regulating autophagy and miR-214 levels in
VHL(+) cells (Figures S7C and S7D). Overall, these data provide
a proof of concept showing that specific targeting of TRPM3 by
small molecule inhibitors may represent a treatment for patients
with ccRCC with increased TRPM3.
DISCUSSION
In this work, we identified VHL as an upstream master regulator
of the robust homeostatic network that tightly regulates starva-
tion autophagy at multiple levels (Figure 8). Because either too
much or not enough autophagy can lead to cell death, there is
a physiological necessity for robust and fine-tuned control of
this process. Several steps of this pathway are inhibited by
converging mechanisms. For example, miR-204 not only directly
represses TRPM3 but also represses it indirectly through CAV1
and directly inhibits accumulation of LC3B. Similarly, protein
levels of LC3B are downregulated by at least two microRNAs,
the expressions of which are regulated differently upstream
(miR-204) and downstream (miR-214) from TRPM3 activity. In
addition, phagophore initiation is controlled by Ca2+ regulation
of AMPK-ULK1 axis.
The robustness of the networks controlling autophagy has
several implications for cancer. Cancer cells develop specific
mechanisms that maintain autophagy and are not present in
noncancer cells. We have demonstrated a connection between(C) Western blot showing steady-state expression levels of ATG16L protein and
(D) Western blot showing the effects of TRPM3KD on the protein expression and
(E) Western blot showing the effects of TRPM3R on the protein expression and p
(F) Western blot showing the effects of TRPM3KD on the protein expression and
(G) Western blot showing the effects of the constitutively active CAMKK2 on the
786-O VHL() TRPM3KD cells. EV, empty virus.
(H) Western blot showing the effects of CAMKK2 shRNA on the accumulation of
(I) Western blot showing the effects of the constitutively active AMPKa2 on the ac
TRPM3KD cells. EV, empty virus.
(J)Western blot showing the effects of AMPKa1/a2 shRNAs on the accumulation o
See also Figure S5.
CanTRPM3 and CAV1, two molecules upregulated in ccRCC, but
additional mechanisms are likely to exist. Disruption of the con-
trolling network at the level of one regulator, particularly down-
stream, may be insufficient to augment autophagy. For example,
loss of miR-214 may be compensated for by miR-204 or inhibi-
tion of phagophore formation. This may explain why pro-onco-
genic, augmented autophagy appears to take place in more
advanced cancers after disruptions at multiple regulatory levels.
On the other hand, cancers such as ccRCC that are associated
with an early loss of VHL, a master regulator of autophagy con-
trol, may become dependent on autophagy much earlier. This
also indicates that the inhibition of oncogenic autophagy may
require directing therapeutics toward multiple targets. Effective
inhibition of autophagy may require a combination of inhibitors
against the TRPM3 and LC3B adaptor protein interaction.
Currently, targeting TRP channels with small molecule agonists
and antagonists is a recognized and clinically used therapeutic
approach for the treatment of chronic, inflammatory, neuro-
pathic, and visceral pain (Brederson et al., 2013). Our study pro-
vides a proof of concept showing that the TRPM3 channel may
be a useful target for the treatment of renal cancer. However,
expression of TRPM3 on pancreatic b cells as a source of Ca2+
and Zn2+ necessary for insulin secretion represents a potential
drawback.
This study also provides an important validated case of an in-
tronic miR-mediated self-loop with negative feedback because
miR-204 inhibits the expression of its host gene product,
TRPM3. Thisminimal regulatory circuit can be predicted by algo-
rithms (Bosia et al., 2012), but there are few well validated exam-
ples, such as miR-126 and EGFL7 (Sun et al., 2010; Nikolic et al.,
2010). The discovery of the miR-204-TRPM3 relationship is
particularly interesting because the expression of miR-204 re-
sults from the VHL-stimulated generation of short transcripts
that do not encode the full-length channel protein (Mikhaylova
et al., 2012). Some stimuli may induce the expression of both
miR-204 and TRPM3.The activity of miR-204 would then
contribute to the return of TRPM3activity to the prestimulus level.
With the role of TRPM3 in cancer growth, this feedback loopmay
be crucial to prevent the progression of oncogenic transfor-
mation. The closest homolog of TRPM3, TRPM1, encodes
miR-211, a paralog of miR-204, in its intron, but TRPM1 does
not have a predicted miR-204/211 site in its 30 UTR. This indi-
cates a specific role of the TRPM3-miR-204 minimal regulatory
loop.
We reported previously that miR-204 is lost in the majority of
ccRCCs compared with adjacent kidney (Mikhaylova et al.,
2012). An independent cohort of ccRCC published by The Can-
cer Genome Atlas Research Network (2013) confirmed thisATG5-ATG12 conjugate in 786-O VHL() control and TRPM3KD cells.
phosphorylation of AMPKa and ULK1 in VHL() cells.
hosphorylation of AMPKa and ULK1 in 786-O VHL() TRPM3KD cells.
phosphorylation of AMPKa and ULK1 in VHL(+) cells.
accumulation of LC3A/LC3B-II and phosphorylation of AMPKa and ULK1 in
LC3A/LC3B-II and phosphorylation of AMPK and ULK1 in 786-O VHL() cells.
cumulation of LC3A/LC3B-II and phosphorylation of AMPK and ULK1 in 786-O
f LC3A/LC3B-II and phosphorylation of AMPK andULK1 in 786-O VHL() cells.
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Figure 6. TRPM3 Regulates Autophagy through miR-214
(A) Normalized levels of miR-214 in 786-O VHL() control, TRPM3KD, and TRPM3R cells.
(B) Normalized levels of miR-214 in 786-O VHL() control, TRPM3KD, and VHL(+) cells.
(C) Normalized levels of miR-214 in VHL() RCC cell lines and the VHL(+) Caki-1 cell line.
(D) Effects of overexpression of TRPM3WT or TRPM3DN on the steady-state levels of miR-214 in the indicated cells.
(E) Effects of TRPM3KD on normalized levels of miR-214 in VHL(+) cells.
(legend continued on next page)
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enhancing responsiveness to treatment in cancer have been
reported (Imamet al., 2012), including in pancreatic cancer (Ohu-
chida et al., 2011), gastric cancer (Sacconi et al., 2012), head
and neck cancer (Lee et al., 2010), neuroblastoma (Ryan et al.,
2012), and glioma (Ying et al., 2013). However, the expression
of miR-204 is induced in insulinomas (Roldo et al., 2006). The
regulation of insulin folding requires Zn2+ entering b cells through
TRPM3 (Wagner et al., 2008, 2010). A high expression of miR-
204, in this case, may be a consequence of increased TRPM3.
ThemiR-214 gene is expressed, together with miR-199a, from
a single noncoding 7.9 kb intronic region located on the opposite
strand of the gene encoding dynamin 3 (DNM3os) (Lee et al.,
2009). This gene is regulated by its own promoter under the con-
trol of the Twist-1 transcription factor (Lee et al., 2009). However,
other transcriptional regulatory mechanisms are not known.
MiR-214 is lost in human ccRCC (Chow et al., 2010, Osanto
et al., 2012). In other cancers, it has tumor-promoting or tu-
mor-suppressing activities, depending on the regulated targets.
One of its targets is the PTEN tumor suppressor (Yang et al.,
2008). MiR-214 also targets components of the ubiquitin protea-
some system, and its decrease contributes to dilated cardiomy-
opathy (Baumgarten et al., 2013). Our identification of miR-214 in
the Ca2+/Zn2+-regulated pathways controlling autophagy is
potentially related to its previously described role as a regulator
of cardiomyocyte Ca2+ homeostasis and survival during cardiac
injury (Aurora et al., 2012).
An important finding of our work is that extracellular Ca2+, and
potentially Zn2+, contributes to the growth of ccRCC by sti-
mulating autophagy. Hypercalcemia is a well documented para-
neoplastic syndrome that also occurs in ccRCC. Parathyroid
hormone-related protein (PTHrP) produced by cancer cells is
considered to be the predominant cause (Pepper et al., 2007).
PTHrP levels are higher in ccRCC compared with other histolog-
ical types, and ccRCCs express PTHrP in 95% of cases (Gotoh
et al., 1993). PTHrP acts as a survival factor for ccRCC, and its
expression is negatively regulated by VHL at the level of mRNA
stability (Danilin et al., 2009). An antibody to the first 34 amino
acids of the PTHrP protein inhibits growth of a SKRC-1 RCC
cell line, indicating that PTHrP is an autocrine growth factor in
RCC (Burton et al., 1990). Multivariate analyses show that PTHrP
expression is comparable with the tumor stage as a significant
prognostic indicator of outcome in advanced ccRCC (Iwamura
et al., 1999). Hypercalcemia in ccRCC patients has been corre-
lated with VEGF expression. VEGF expression is then correlated
to PTHrP levels (Feng et al., 2013). In view of our data, we pro-
pose that hypercalcemia may support the growth of ccRCC
through the promotion of oncogenic autophagy.(F) Effects of treatment with the indicated concentrations of pre-miR-214 and ant
were treated with CQ.
(G) Effects of anti-miR-214 (lentivirus, lenti) treatments on the accumulation of LC
CQ-treated cells are shown.
(H) Effects of lentiviral anti-miR-214 and pre-miR-214 treatments on the accumu
(I) Effects of pre-miR-214 on the activity of luciferase reporter constructs contain
786-O VHL() cells.
(J) Effects of constitutively active CAMKK2 and AMPKa2 on the accumulation of
(K) Effects of CAMKK2, AMPKa1/2, ULK1, and PIK3C3 knockdowns on the accu
(L) Effects of anti-miR214 on the accumulation of LC3A and LC3B in 786-O VHL
In all panels, n represents a number of individual experiments in triplicate. If n < 3
CanIn summary, we have identified a regulatory network under the
VHL tumor suppressor that, when released from VHL control,
contributes to the growth of ccRCC. Importantly, this network
has several potential targets that can be investigated for thera-
peutic interventions.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments
Human VHL() and VHL(+) 786-O, A498, andCaki-1 cells have been described
previously (Mikhaylova et al., 2008; Yi et al., 2010). All cell lines are authenti-
cated periodically (Genetica). Unless indicated otherwise, experiments were
performed with the following time line: cells (10–203 104 cells/ml) were plated
in medium with 10% serum. After 24 hr, the medium was changed to contain
0.1% serum, and cells were collected 48 hr later. Specific treatments were
applied during the 48 hr period. For rescue experiments, cells were transfected
with plasmids or transduced with viruses and, 24 hr later, starved for 48 hr.
For autophagosome and LC3 experiments, cells were treated with 100 mM
CQ for 1 hr before collection. In all relevant experiments, controls were treated
with empty or scrambled viruses or plasmids. Cells were collected in radio-
immunoprecipitation assay buffer. Five to thirty micrograms of extracts were
separated on 10% or 4%–12% polyacrylamide gels and transferred onto a
polyvinylidene fluoridemembrane. Blotswere probedwith relevant antibodies.
RNA extractions and quantitative RT-PCR (qRT-PCR) have been described
before (Mikhaylova et al., 2012). The primer sequences, antibodies, and chem-
icals used are listed in the Supplemental Experimental Procedures.
Human RCC Tumors
Fresh-frozen samples or paraffin-embedded samples of ccRCC and matched
normal kidney were obtained and analyzed for the VHL gene sequence and
protein expression as described previously (Yi et al., 2010). All human samples
were from anonymous donors and exempt from the Institutional Review Board
protocol. Lysates were analyzed for proteins of interest using semiquantitative
immunoblotting (Yi et al., 2010; Mikhaylova et al., 2012).
Constructs and Plasmids
The following miR reagents were used. Pre-miR-204 and pre-miR-214 pre-
cursors and pre-miR negative controls were purchased from Ambion. Anti-
miR-204 and 214 and negative controls were purchased from Dharmacon.
Lentivector-basedmicroRNA precursor construct miR-204 andmiR-214,miR-
Zip lentivector-based anti-microRNA-204 and anti-microRNA-214, and nega-
tive controls were obtained from System Biosciences. The GoClone luciferase
30 UTR chimeric constructs of LC3s and TRPM3 were purchased from Switch-
gear Genomics. To alter the miR-214 binding sequence, the core CCTGCTG
sequence in the 30 UTR of LC3A was mutated to AGTTGTC, and the core
CTGCTGA sequence in the 30 UTR of LC3B was mutated to GTTGTC (Gen-
Script). To alter the miR-204 binding site, the core GGG sequence in the 30
UTR of TRPM3 was replaced with TTT. The 30 UTR of CAV1 was cloned into
SpeI/MluI sites of the pMIR-REPORT luciferase construct (Ambion), and the
core GGG sequence was mutated to CCC. All shRNA constructs were pur-
chased from Open Biosystems. A list of shRNAs used is provided in the Sup-
plemental Experimental Procedures. Lentiviral DNA constructs were VSV-G
envelope-packaged (Cincinnati Children’s Hospital Medical Center (CCHMC),
Viral Vector Core). For stable pooled cells, transduction was followed byi-miR-214 on the accumulation of LC3A/LC3B in starved VHL() cells. All cells
3A/LC3B in starved 786-O VHL() TRPM3KD cells. In the case of siRNA, only
lation of LC3A/B in starved 786-O VHL(+) cells.
ing LC3A or LC3B 30 UTRs with either WT or mutated miR-214 binding sites in
miR-214 in starved 786-O VHL() TRPM3KD cells.
mulation of miR-214 in starved 786-O VHL() cells.
() cells treated with STO-609.
, error bars indicate SD. If nR 3, error bars indicate SEM. See also Figure S6.
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Figure 7. The Effects of TRPM3KD Are Reproduced by MFA, a Small Molecule Blocker of TRPM3
(A) Box-and-whisker plot showing the growth of subcutaneous xenograft tumors formed by the indicated VHL() cells in mice treated with MFA, IDM, or vehicle.
Open circles represent points that are outside of the 1.5 interquartile range from the box.
(B) Representative sections of 786-O tumors from each treatment group stained for Ki67 and bar graph quantification performed as in Figure 1F. Scale bar,
100 mM.
(C) Effects of treatment with MFA on the expression of endogenous TRPM3 measured by western blot and by qRT-PCR in VHL() cells.
(D) Effects of MFA treatments of 786-O and A498 VHL() cells on the accumulation of LC3A/LC3B-II and phosphorylation of ULK1-Ser317. R, ratio of p-ULK1-
Ser317 to total ULK1.
(E) Effects of MFA on accumulation of miR-214 in 786-O and A498 VHL() cells.
In all panels, error bars indicate SEM. See also Figure S7.
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TRPM3 Channel in Clear Cell Renal Cell Carcinomaplasmid-appropriate selection. TRPM3 wild-type and mutated constructs had
yellow fluorescent protein fused to the C terminus and were expressed from
the pcDNA3.1 plasmid (Hoffmann et al., 2010). The TRPM3 shRNA-insensitive
mutant was obtained by synonymous mutation of the shRNA binding site and
replacement of the neomycin selection marker with a zeocin cassette in
pcDNA3.1 (GenScript). The construct of constitutively active FLAG-tagged
CAMKK2 was obtained from Addgene (plasmid no. 33324), and the cDNA
was subcloned into the pSMPUW-Hygro lentiviral construct (Cell Biolabs).
The lentiviral construct of constitutively active myc-tagged AMPKa2 was ob-
tained from Dr. B. Dasgupta (CCHMC).
Transfection and Transduction
For plasmid transfections, we used Fugene or Lipofectamine. For microRNA
constructs or pooled siRNA transfections, we used Lipofectamine 2000. All
were performed according to the manufacturer’s protocol. Transductions750 Cancer Cell 26, 738–753, November 10, 2014 ª2014 Elsevier Incwith lentiviral particles were performed using 2 mg/ml Polybrene. The luciferase
activity of the GoClone 30 UTR reporter constructs was measured using a
LightSwitch luciferase assay kit (Switchgear Genomics) according to the man-
ufacturer’s protocol. The luciferase activity of the pMIR-REPORT construct
containing the CAV1 30 UTR was measured using a standard luciferase assay
kit (Promega) using cotransfection ofRenilla luciferase for normalization. All re-
sults are shown as a ratio of the effect of the miR mimetic to the effect of the
nontargeting control.
Mouse Xenografts
Experiments on mice were performed in accordance with University of Cincin-
nati Institutional Animal Care and Use Committee-approved protocols. For in-
trakidney injections, 53 104 cells were resuspended in 50%Matrigel to a final
volume of 30 ml and then injected slowly into the subcapsular renal paren-
chyma of 4- to 5-week-old athymic nude mice. Tumors were collected after.
Figure 8. Model Summarizing the Proposed Regulatory Network
Controlling Oncogenic LC3A/LC3B Autophagy
Black lines, oncogenic pathways; gray lines, tumor-suppressing pathways;
asterisk, work reported by Mikhaylova et al. (2012).
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TRPM3 Channel in Clear Cell Renal Cell Carcinoma10–12weeks. For subcutaneous injections, 13 106 cells in cell culturemedium
containing 50% Matrigel were injected into the flanks of athymic nude mice.
Three standard dimensions of the tumor were measured, and the volume of
the tumor was calculated using the equation d1 3 d2 3 d3 3 p / 6. After 2-
3 weeks, these tumors reached an approximate average volume of 50 mm3,
and mice were randomly assigned to treatment groups. At the end of the ex-
periments, mice were sacrificed, and tumors were fixed in 4% paraformalde-
hyde and processed for immunocytochemistry using anti-Ki67, anti-LC3B,
and anti-caspase 3 antibodies. Ki-67-stained nuclei were counted as
described before (Mikhaylova et al., 2012).
Immunocytochemistry, Immunofluorescence, and TEM
For immunocytochemistry, sections of fixed and paraffin-embedded tumors
were processed in the Pathology Research Core at CCHMC. For immunoflu-
orescence, cells were plated and treated as described before (Mikhaylova
et al., 2012), and images were acquired on a Zeiss LSM710 confocal micro-
scope or on a Zeiss Axioplan 2 microscope with the appropriate filter cubes
and a Zeiss Axiocam MRm to record the images. The number of puncta per
cell and the number of cells expressing puncta versus the total number of cells
were counted manually in five independent fields containing between 50–100
cells, or three to five sections were counted for each type of tumor. TEM sam-
ples were processed in the ElectronMicroscopy Core at CCHMC as described
before (Mikhaylova et al., 2012).
Calcium Imaging
Cell suspensions were incubated with RPMI-1640 medium containing 10 mM
Indo-1 (Life Technologies) for 30 min at 37C in the dark with repeated
mixing. Cells were then washed twice with RPMI-1640 medium and resus-
pended at 2 3 106 cells/ml. Prewarmed samples were first analyzed for
2 min at about 2,000 events/s to establish the baseline. Then PS or PS
and EGTA were quickly added to the suspension, and cells were further
acquired for another 200 ms before ionomycin was added as the positive
control for Ca2+ influx. Measurements were performed using a BD-LSR fluo-
rescence-activated cell sorting machine equipped with UV lasers in the Flow
Cytometry Core at Shriners Hospital for Children in Cincinnati. Ratiometric
analyses of Indo-1 violet to Indo-1 blue were performed using FlowJo
software.
Statistical Analysis
For descriptive statistics, data are expressed as mean ± SEM unless indicated
otherwise. Analysis of differential expression was performed using ANOVA fol-
lowed by Tukey-Kramer multiple comparison tests. For the analysis of tumor
growth, repeated-measures ANOVA (parametric and nonparametric) were
performed. Standard box-and-whisker plots were used to compare distribu-
tions of the normalized abundance measure for individual proteins. Correla-Cantions between variables were assessed by means of regression analysis and
by Pearson correlation coefficient. All data were log2-transformed to facilitate
robust and outlier-insensitive analyses. Differences of p < 0.05 were consid-
ered to be statistically significant.
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